Sanifit raises $41M for late-stage R&D program

Forbion has joined a syndicate backing a $41 million round for Spain's Sanifit, which is plotting a Phase IIb study of its lead drug SNF472, which is designed to treat cardiovascular disease related to calcification in patients with end-stage renal disease. That should be enough money to get the company through late stage development for calciphylaxis. The biotech also announced that it had named longtime GSK vet Russell Greig as chairman of the board. The round was led by Ysios Capital and included Lundbeckfond Ventures, Gilde Healthcare, Edmond de Rothschild Investment Partners, "la Caixa" and Baxter Healthcare. Release

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.